PMID- 32796717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 11
TI  - Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or 
      Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study.
LID - 10.3390/jcm9082608 [doi]
LID - 2608
AB  - We aimed to assess the efficacy of biologic therapy in refractory non-Multiple 
      Sclerosis (MS) Optic Neuritis (ON), a condition more infrequent, chronic and 
      severe than MS ON. This was an open-label multicenter study of patients with 
      non-MS ON refractory to systemic corticosteroids and at least one conventional 
      immunosuppressive drug. The main outcomes were Best Corrected Visual Acuity 
      (BCVA) and both Macular Thickness (MT) and Retinal Nerve Fiber Layer (RNFL) using 
      Optical Coherence Tomography (OCT). These outcome variables were assessed at 
      baseline, 1 week, and 1, 3, 6 and 12 months after biologic therapy initiation. 
      Remission was defined as the absence of ON symptoms and signs that lasted longer 
      than 24 h, with or without an associated new lesion on magnetic resonance imaging 
      with gadolinium contrast agents for at least 3 months. We studied 19 patients (11 
      women/8 men; mean age, 34.8 +/- 13.9 years). The underlying diseases were Bechet's 
      disease (n = 5), neuromyelitis optica (n = 3), systemic lupus erythematosus (n = 
      2), sarcoidosis (n = 1), relapsing polychondritis (n = 1) and anti-neutrophil 
      cytoplasmic antibody -associated vasculitis (n = 1). It was idiopathic in 6 
      patients. The first biologic agent used in each patient was: adalimumab (n = 6), 
      rituximab (n = 6), infliximab (n = 5) and tocilizumab (n = 2). A second 
      immunosuppressive drug was simultaneously used in 11 patients: methotrexate (n = 
      11), azathioprine (n = 2), mycophenolate mofetil (n = 1) and hydroxychloroquine 
      (n = 1). Improvement of the main outcomes was observed after 1 year of therapy 
      when compared with baseline data: mean +/- SD BCVA (0.8 +/- 0.3 LogMAR vs. 0.6 +/- 0.3 
      LogMAR; p = 0.03), mean +/- SD RNFL (190.5 +/- 175.4 mum vs. 183.4 +/- 139.5 mum; p = 
      0.02), mean +/- SD MT (270.7 +/- 23.2 mum vs. 369.6 +/- 137.4 mum; p = 0.03). Besides, 
      the median (IQR) prednisone-dose was also reduced from 40 (10-61.5) mg/day at 
      baseline to. 2.5 (0-5) mg/day after one year of follow-up; p = 0.001. After a 
      mean +/- SD follow-up of 35 months, 15 patients (78.9%) achieved ocular remission, 
      and 2 (10.5%) experienced severe adverse events. Biologic therapy is effective in 
      patients with refractory non-MS ON.
FAU - Herrero-Morant, Alba
AU  - Herrero-Morant A
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Alvarez-Reguera, Carmen
AU  - Alvarez-Reguera C
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Martin-Varillas, Jose L
AU  - Martin-Varillas JL
AD  - Rheumatology, Hospital Sierrallana, Barrio Ganzo, s/n, 39300 Torrelavega, Spain.
FAU - Calvo-Rio, Vanesa
AU  - Calvo-Rio V
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Casado, Alfonso
AU  - Casado A
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Prieto-Pena, Diana
AU  - Prieto-Pena D
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Atienza-Mateo, Belen
AU  - Atienza-Mateo B
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Maiz-Alonso, Olga
AU  - Maiz-Alonso O
AD  - Rheumatology and Ophtalmology, Hospital de Donostia, Paseo Dr. Begiristain, 117, 
      20080 Donostia, Spain.
FAU - Blanco, Ana
AU  - Blanco A
AD  - Rheumatology and Ophtalmology, Hospital de Donostia, Paseo Dr. Begiristain, 117, 
      20080 Donostia, Spain.
FAU - Vicente, Esther
AU  - Vicente E
AD  - Rheumatology, Hospital Universitario de La Princesa, C/Diego de Leon, 62, 28006 
      Madrid, Spain.
FAU - Rua-Figueroa, Inigo
AU  - Rua-Figueroa I
AUID- ORCID: 0000-0002-7894-1690
AD  - Rheumatology, Hospital Universitario de Gran Canaria Doctor Negrin, C/Plaza 
      Barranco de la Ballena, s/n, 35010 Las Palmas de Gran Canaria, Spain.
FAU - Caceres-Martin, Laura
AU  - Caceres-Martin L
AD  - Rheumatology, Hospital Universitario de Gran Canaria Doctor Negrin, C/Plaza 
      Barranco de la Ballena, s/n, 35010 Las Palmas de Gran Canaria, Spain.
FAU - Garcia-Serrano, Jose L
AU  - Garcia-Serrano JL
AD  - Internal Medicine and Ophtalmology, Hospital San Cecilio, Av. del Conocimiento, 
      s/n, 18016 Granada, Spain.
FAU - Callejas-Rubio, Jose Luis
AU  - Callejas-Rubio JL
AD  - Internal Medicine and Ophtalmology, Hospital San Cecilio, Av. del Conocimiento, 
      s/n, 18016 Granada, Spain.
FAU - Ortego-Centeno, Norberto
AU  - Ortego-Centeno N
AD  - Internal Medicine and Ophtalmology, Hospital San Cecilio, Av. del Conocimiento, 
      s/n, 18016 Granada, Spain.
FAU - Narvaez, Javier
AU  - Narvaez J
AUID- ORCID: 0000-0002-1614-8064
AD  - Rheumatology, Hospital de Bellvitge, Carrer de la Feixa Llarga, s/n, 08907 
      L'Hospitalet de Llobregat, Spain.
FAU - Romero-Yuste, Susana
AU  - Romero-Yuste S
AD  - Rheumatology, Complejo Hospitalario Universitario de Pontevedra, Loureiro Crespo, 
      2, 36002 Pontevedra, Spain.
FAU - Sanchez, Julio
AU  - Sanchez J
AD  - Rheumatology, Hospital Universitario 12 de Octubre, Av. de Cordoba, s/n, 28041 
      Madrid, Spain.
FAU - Estrada, Paula
AU  - Estrada P
AUID- ORCID: 0000-0002-9827-5680
AD  - Rheumatology, Hospital de Sant Joan Despi Moises Broggi, Carrer de Jacint 
      Verdaguer, 90, 08970 Sant Joan Despi, Spain.
FAU - Demetrio-Pablo, Rosalia
AU  - Demetrio-Pablo R
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Martinez-Lopez, David
AU  - Martinez-Lopez D
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Castaneda, Santos
AU  - Castaneda S
AD  - Rheumatology, Hospital Universitario de La Princesa, C/Diego de Leon, 62, 28006 
      Madrid, Spain.
FAU - Hernandez, Jose L
AU  - Hernandez JL
AUID- ORCID: 0000-0002-6585-8847
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Gonzalez-Gay, Miguel A
AU  - Gonzalez-Gay MA
AUID- ORCID: 0000-0002-7924-7406
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
FAU - Blanco, Ricardo
AU  - Blanco R
AUID- ORCID: 0000-0003-2344-2285
AD  - Rheumatology, Ophtalmology and Internal Medicine, Hospital Universitario Marques 
      de Valdecilla, Av. de Valdecilla, 25, 39008 Santander, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200811
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7464396
OTO - NOTNLM
OT  - adalimumab
OT  - biologic therapy
OT  - infliximab
OT  - optic neuritis
OT  - rituximab
OT  - tocilizumab
COIS- Disclosures that might be interpreted as constituting of possible conflict(s) of 
      interest for the study: Dr. Jose L. Martin-Varillas received grants/research 
      supports from AbbVie, Pfizer, Lilly, Janssen and Celgene; Dr. Vanesa Calvo-Rio 
      received grants/research supports from MSD and Roche and had consultation 
      fees/participation in company-sponsored speaker's bureau from Abbott, Lilly, 
      Celgene, Grunenthal and UCB Pharma; Dr. Ana Blanco had consultation 
      fees/participation in company-sponsored speaker's bureau from AbbVie. Dr. Javier 
      Narvaez had consultation fees/participation in the company-sponsored speaker's 
      bureau from Bristol-Myers Squibb. Professor Miguel A. Gonzalez-Gay received 
      grants/research supports from AbbVie, MSD, Jansen and Roche and had consultation 
      fees/participation in company-sponsored speaker's bureau from AbbVie, Pfizer, 
      Roche, Sanofi, Lilly, Celgene and MSD. Dr. Ricardo Blanco received 
      grants/research supports from AbbVie, MSD and Roche and had consultation 
      fees/participation in company-sponsored speaker's bureau from AbbVie, Pfizer, 
      Roche, Bristol-Myers, Janssen, Novartis, Sanofi, Lilly and MSD. The following 
      authors did not declare financial disclosures: Alba Herrero-Morant, Carmen 
      Alvarez-Reguera, Alfonso Casado, Diana Prieto-Pena, Belen Atienza-Mateo, Olga 
      Maiz-Alonso, Esther Vicente, Inigo Rua-Figueroa, Laura Caceres-Martin, Jose L. 
      Garcia-Serrano, Jose Luis Callejas-Rubio, Norberto Ortego-Centeno, Susana 
      Romero-Yuste, Julio Sanchez, Paula Estrada, Rosalia Demetrio-Pablo, David 
      Martinez-Lopez, Santos Castaneda and Jose L. Hernandez.
EDAT- 2020/08/17 06:00
MHDA- 2020/08/17 06:01
PMCR- 2020/08/11
CRDT- 2020/08/16 06:00
PHST- 2020/06/21 00:00 [received]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/08/16 06:00 [entrez]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2020/08/17 06:01 [medline]
PHST- 2020/08/11 00:00 [pmc-release]
AID - jcm9082608 [pii]
AID - jcm-09-02608 [pii]
AID - 10.3390/jcm9082608 [doi]
PST - epublish
SO  - J Clin Med. 2020 Aug 11;9(8):2608. doi: 10.3390/jcm9082608.